LIG3 and plasma cell myeloma: Furthermore, MALAT1 has been shown to modulate the alternative NHEJ (A-NHEJ) pathway by directly interacting with LIG3 and PARP1 in multiple myeloma cells and targeting MALAT1 enhances sensitivity to PARPi or proteasomal inhibitors (69).